U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Substance Class Structurally Diverse
Created
by admin
on Fri Dec 15 18:48:46 GMT 2023
Edited
by admin
on Fri Dec 15 18:48:46 GMT 2023
Source Materials Class ORGANISM
Source Materials Type BACTERIUM
Source Materials State LIVE
Organism Family Mycobacteriaceae
Organism Genus Mycobacterium
Organism Species tuberculosis
Author (ZOPF, 1883) LEHMANN AND NEUMANN, 1896
Part WHOLE
Record UNII
R0EM8D5HFD
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MYCOBACTERIUM TUBERCULOSIS
WHO-DD  
Common Name English
MYCOBACTERIUM TUBERCULOSIS TYPUS HUMANUS WHOLE
Common Name English
MYCOBACTERIUM TUBERCULOSIS VAR. HOMINIS WHOLE
Common Name English
Mycobacterium tuberculosis [WHO-DD]
Common Name English
BACTERIUM TUBERCULOSIS WHOLE
Common Name English
BACILLUS TUBERCULOSIS WHOLE
Common Name English
MYCOBACTERIUM TUBERCULOSIS WHOLE
Systematic Name English
M. tuberculosis
Common Name English
MYCOBACTERIUM TUBERCULOSIS (ZOPF, 1883) LEHMANN AND NEUMANN, 1896
Systematic Name English
MYCOBACTERIUM TUBERCULOSIS TUBERCULOSIS WHOLE
Systematic Name English
M-Tb
Common Name English
Code System Code Type Description
FDA UNII
R0EM8D5HFD
Created by admin on Fri Dec 15 18:48:46 GMT 2023 , Edited by admin on Fri Dec 15 18:48:46 GMT 2023
PRIMARY
RXCUI
1492936
Created by admin on Fri Dec 15 18:48:46 GMT 2023 , Edited by admin on Fri Dec 15 18:48:46 GMT 2023
PRIMARY RxNorm
NCBI TAXONOMY
1773
Created by admin on Fri Dec 15 18:48:46 GMT 2023 , Edited by admin on Fri Dec 15 18:48:46 GMT 2023
PRIMARY
DAILYMED
R0EM8D5HFD
Created by admin on Fri Dec 15 18:48:46 GMT 2023 , Edited by admin on Fri Dec 15 18:48:46 GMT 2023
PRIMARY
ITIS
963806
Created by admin on Fri Dec 15 18:48:46 GMT 2023 , Edited by admin on Fri Dec 15 18:48:46 GMT 2023
PRIMARY
Related Record Type Details
INHIBITOR->TARGET ORGANISM
Despite its broad structural similarity to EMB retained good activity against EMB-resistant Mtb strains (MIC 2.4 μM, cf. 1.2 μMNagainst H37Rv).
MIC
VACCINE ANTIGEN->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
VACCINE ANTIGEN->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
MIC
VACCINE ANTIGEN->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
VACCINE ANTIGEN->TARGET ORGANISM
VACCINE ANTIGEN->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
MIC90
VACCINE ANTIGEN->TARGET ORGANISM
VACCINE ANTIGEN->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR -> TARGET
INHIBITOR->TARGET ORGANISM
Demonstrates efficacy in a rodent model of tuberculosis.
MIC
VACCINE ANTIGEN->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR -> TARGET
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
Intracellular M. Tb
IC50
INFRASPECIFIC -> PARENT ORGANISM
VACCINE ANTIGEN->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
A broad spectrum antibiotic.In phase I clinical trials, found to have better safety (milder side effects) than LZD due to its more rapid clearance,88 although final results from a phase IIa EBA study may suggest lower efficacy than both LZD and sutezolid.
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
40 strains
MIC90
INFRASPECIFIC -> PARENT ORGANISM
VACCINE ANTIGEN->TARGET ORGANISM
INFRASPECIFIC -> PARENT ORGANISM
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
VACCINE ANTIGEN->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
VACCINE ANTIGEN->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
MIC
INHIBITOR->TARGET ORGANISM
INHIBITOR->TARGET ORGANISM
VACCINE ANTIGEN->TARGET ORGANISM
Related Record Type Details
ACTIVE MOIETY